[Articles] Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial

# Editorial Summary

Myasthenia gravis is a serious autoimmune condition where the body's immune system mistakenly attacks the nerves and muscles, causing progressive weakness and fatigue. For patients living with this condition, finding effective treatments that are also convenient to manage is crucial. A new study published in *The Lancet* has evaluated cemdisiran, an experimental therapy designed to help control the immune response that causes the disease.

The research, part of a large clinical trial called NIMBLE, tested cemdisiran both as a standalone treatment and combined with other myasthenia gravis medications. Patients received injections under the skin every three months rather than daily pills or frequent hospital visits. The results were encouraging: the treatment proved effective at improving muscle strength and function, and most patients tolerated it well without serious safety concerns. This quarterly injection approach could represent a significant improvement in how patients manage their condition day-to-day.

While these findings are positive, it's important to note that cemdisiran is still in the late stages of clinical testing and is not yet widely available. Like all medications, it carries potential side effects that doctors and patients would need to discuss carefully. The therapy appears most suited for generalised myasthenia gravis—the most common form of the disease—rather than milder variants.

If you or a loved one has myasthenia gravis, discuss this emerging treatment option with your neurologist to understand whether it might be appropriate when it becomes available. In the meantime, continue following current treatment plans and maintaining regular medical appointments to monitor your condition.